Healthcare Industry
Filter News
Found 19,369 articles
-
Following a nine-month review, the Biden administration will issue a framework for the National Institutes of Health to implement so-called “march-in rights” under the Bayh-Dole Act of 1980.
-
With the biopharma industry’s looming wave of gene therapy submissions and potential approvals, the senior senator is laying the groundwork for a legislative initiative to improve access to these expensive treatments.
-
Fueled partly by increasing lifespans and cancer incidence, the area’s worth is projected to soar to 13.67 billion by 2032, Precedence Research reports.
-
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
12/6/2023
ImmunoPrecise Antibodies Ltd. announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share.
-
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
12/6/2023
Kamada Ltd. announced the execution of a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement between the parties.
-
Axogen Announces Transition of Finance Team Leadership
12/6/2023
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately.
-
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy
12/6/2023
CDR-Life Inc. announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy.
-
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
12/6/2023
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, highlighted the presentation of analytical and clinical validation data on a novel prognostic test in early-stage lung cancer, generated through collaboration with the Samsung Medical Centre and AstraZeneca (LSE/STO/Nasdaq: AZN).
-
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
12/5/2023
Johnson & Johnson is hosting a meeting with the investment community at the New York Stock Exchange to present the Company’s overarching strategy, its diverse and robust Innovative Medicine and MedTech pipelines and long-term financial outlook.
-
Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncology
12/5/2023
Syapse® and the FDA Oncology Center of Excellence renewed a four-year agreement to collaboratively develop and implement specific research projects to advance the use of real-world data and explore the potential strengths and limitations of using real-world evidence to inform regulatory objectives.
-
MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis
12/5/2023
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through Synthia™ retrosynthesis software application programing interface integration.
-
Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836
12/5/2023
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, announced that it has received a grant of over USD 1.5M from the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health.
-
ANGLE launches Portrait+ CTC kit at SABCS
12/5/2023
ANGLE plc is delighted to announce the launch of its Portrait®+ CTC staining kit at the San Antonio Breast Cancer Symposium.
-
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
12/5/2023
RELIEF THERAPEUTICS Holding SA announced its intent to progressively transition from a direct marketing and sales infrastructure for its commercial-stage assets to a partnership-based model.
-
STRATA Skin Science Announces Strengthening of Leadership Team
12/4/2023
STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced the promotion of Shmuel Gov to Chief Operating Officer.
-
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023
12/4/2023
Champions Oncology, Inc., a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close.
-
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
12/4/2023
CEL-SCI Corporation announced that the British National Institute for Health and Care Excellence has selected Multikine* to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck in the UK.
-
AAOS Designates Gwo-Chin Lee, MD, FAAOS, Editor-In-Chief of JAAOS Global Research & Reviews
12/4/2023
The American Academy of Orthopaedic Surgeons announced Gwo-Chin Lee, MD, FAAOS, as the new editor-in-chief of the Journal of the AAOS Global Research & Reviews®.
-
OrthoPediatrics Corp. to Host Educational and Networking Events at 19th Annual International Pediatric Orthopaedic Symposium (IPOS)
12/4/2023
OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced plans to host educational and networking events at IPOS and its increased support of the event as an Emerald-Level sponsor.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 04, 2023
12/4/2023
Blueprint Medicines Corporation, announced that, effective December 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 2,503 shares of its common stock and an aggregate of 1,251 restricted stock units to two new employees under Blueprint Medicines' 2020 Inducement Plan.